Research progress on α7 nicotinic acetylcholine receptor in lung cancer
- VernacularTitle:α7烟碱型乙酰胆碱受体在肺癌中作用的研究进展
- Author:
Hanbo PAN
1
;
Qingquan LUO
1
Author Information
1. Department of Thoracic Surgical Oncology, Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200030, P. R. China
- Publication Type:Journal Article
- Keywords:
Lung cancer;
α7 nicotinic acetylcholine receptor;
nicotine;
review
- From:
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery
2023;30(06):917-923
- CountryChina
- Language:Chinese
-
Abstract:
Lung cancer is one of the most prevalent and deadly malignances worldwide. Cigarette smoking has been identified to be the major risk factor of lung cancer, and nicotine is one of the most harmful components in tobacco smoke. Nicotinic acetylcholine receptors (nAChRs) are universally expressed in mammalian cells, including tumor cells, and perform various critical biological functions. α7nAChR, an important member of nAChRs family, possesses a high affinity for nicotine and plays a core role in the nicotine-mediated lung cancer cell proliferation, angiogenesis, invasion and metastasis. Nowadays, lots of α7nAChR antagonists have been found to inhibit lung cancer cell proliferation, invasion and angiogenesis in vitro and in vivo, and therefore prevented disease progression. These studies indicated that α7nAChR might be a potential target in treating lung cancer. In this review, we summarized the current researches on α7nAChR in the progress of lung cancer.
